The anemia that is most common in patients with solid tumors is the anemia of chronic disease, which probably occurs because of im paired production and a diminished response to serum erythropoietin (EPO). A number of trials evaluating recombinant human EPO in anemic cancer patients with a variety of solid tumors have demonstrated effective response rates, with increases in hemoglobin (Hb) concentra tion and reduction or elimination of transfusion requirements. The anemia of certain solid tu mors (eg, lung cancer, prostate cancer) appears to respond better to recombinant human EPO therapy than does the anemia associated with other cancers (eg, colon cancer). Both tumor response and increases in Hb concentrations are important factors in improving the quality of life of patients. The greatest contributor to improved quality of life appears to be the nor malization of Hb levels.
Thatcher N.Management of chemotherapy-induced anemia in solid tumors. Semin Oncol.1998;25:23-26.
2.
Henry DH, Abels RIRecombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol.1994; 21:21-28.
3.
Pawlicki M., Jassem J., Bosze P., et al. A multicenter study of recombinant human erythropoietin (epoetin α) in the management of anemia in cancer patients receiving chemotherapy. Anticancer Drugs. 1997;8:949-957.
4.
Oberhoff C., Neri B., Amadori D., et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol.1998 ;9:255-260.
5.
Glaspy J., Bukowski R., Steinberg D., et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol.1997;15:1218-1234.
6.
Demetri GD, Kris M., Wade J., et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol.1998;16:3412-3425.
7.
Ludwig H., Sundal E., Pecherstorfer M., et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer. 1995; 76:2319-2329.
8.
Markman M., Reichman B., Hakes T., et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol.1993;49:172-176.
9.
Cascinu S., Fedeli A., Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol.1994;12:1058-1062.
10.
Cazzola M., Ponchio L., Beguin Y., et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: results of a phase I/II clinical trial. Blood.1992;79:29-37.
11.
Cazzola M., Messinger D., Battistel V., et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood. 1995 ;86:4446-4453.
12.
Osterborg A. , Boogaerts MA, Cimino R., et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma—a randomized multicenter study. The European Study Group of Erythropoietin (epoetin beta) treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood. 1996;87:2675-2682.
13.
Abels RIUse of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol.1992;19:29 -35.
14.
Ludwig H., Fritz E., Leitgeb C., et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol.1993;4:161-167.
15.
Ludwig H., Pecherstorfer M., Leitgeb C., Fritz E.Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells.1993:11:348-355.
16.
Dowlati A., R'Zik S, Fillet G, Beguin Y. Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production. Br J Haematol. 1997;97:297-299.
17.
Sawabe Y., Takiguchi Y., Kikuno K., et al. Changes in levels of serum erythropoietin, serum iron, and unsaturated iron binding capacity during chemotherapy for lung cancer. Jpn J Clin Oncol.1998;28: 182-186.
18.
de Campos E., Radford J., Steward W., et al. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol.1995;13:1623-1631.
19.
Zarogoulidis K., Papagiannis A., Ziogas E., et al. Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer. Eur J Cancer. 1997;33:2428-2431.
20.
Braga M., Gianotti L., Gentilini O., et al. Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery. Hepatogastroenterology. 1997;44:685-690.
21.
Heiss MM, Tarabichi A., Delanoff C., et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer: a double-blind randomized study. Surgery . 1996; 119:523-527.
22.
Glimelius B. , Linne T., Hoffman K., et al. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol.1998;16:434 - 440.
23.
Strum SB, McDermed JE, Scholz MC, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol.1997;79:933-941.
24.
Beshara S., Letocha H., Linde T., et al. Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin. Prostate. 1997;31:153-160.
